to chronic disease
Michael Motschmann has been an entrepreneur for over 20 years, and during this time has been actively involved in the formation and setting up of several companies in Austria and abroad. Until a company sale in December 2007, he was managing partner of one of the biggest steel hardening companies in Germany. In 2004, Mr. Motschmann co-founded MIG Verwaltungs-AG, and as a member of the Board of Management he is Head of the participations division. MIG AG is a management company for various VC funds which are financed by private investors and which invest in participations in companies in Germany and Austria, mainly in the life science and high-tech fields. Michael Motschmann is on the Supervisory Boards of several non-listed companies.
Helmut W. Jeggle
Helmut Jeggle is Head of Business Planning & Analyzing at ATHOS Service GmbH in Munich. He studied business administration at the FH Neu-Ulm and earned the degree Diplom-Betriebswirt. In the year 2000 he started at HEXAL AG. After a two-year trainee program he took over the management of the controlling department for Germany and from 2004 he was head of the global controlling department of HEXAL AG. During this time he was a significant contributor in the sales processes of Betapharm and HEXAL AG. From March until the end of October 2005 he was a member of the integration office of Sandoz International/HEXAL AG. As of November 1, 2005 he overtook the supervision of the division Business Planning & Analyse Germany. In parallel he earned his MBA (Master of Business Administration) at the Stuttgart Institute of Management and Technology (SIMT). Since July 1, 2007 he is responsible for the area of Pharma/Biotech at ATHOS Service GmbH.
Mr. Jeggle is a member of numerous Supervisory Boards.
Prof. Dr. Christoph Huber
Prof. Dr. Christoph Huber is professor emeritus at the Johannes-Gutenberg University Mainz, former head of the Department of Hematology and Oncology at the Mainz University Medical Center and an international leader in the field of immuno-oncology. He chairs Europe´s Association for Cancer Immunotherapy (CIMT), is board member of the Ci3 Cluster of Individualized ImmunIntervention e.V at the Rhine-Main Metropolitan Area and senior advisor to international pharmaceutical companies, science-driven SMEs and Big Science Institutions. Prof. Huber is also co-founder of BioNTech AG and of Ganymed Pharmaceuticals AG.
Noel Barrett, PhD
Noel Barrett is a distinguished business leader in the field of vaccines. He has more than 30 years’ experience in the vaccine and biologics industry with management responsibilities covering the complete development process required to bring vaccine products to the market. In his prior position as Vice President Global R&D Vaccines at Baxter Healthcare he led the development and licensure of Baxter’s FSME Tick-borne encephalitis vaccine, Meningococcus C, cell-culture derived H5N1, H1N1 and seasonal influenza vaccines (Preflucel).
His contribution to the Baxter scientific community was recognised with the title of Baxter Distinguished Scientist, the most prestigious scientific recognition within the company and the Baxter Bioscience President’s Leadership Award.
Mag. Vera Bürger
Mag. Vera Bürger has been a project manager for the clinical department of AFFiRiS AG since 2009. Following a one year sabbatical in the US, she completed her studies in nutritional science at the University of Vienna. Ms. Bürger brings several years of experience in the pharmaceutical industry (Abbott, Lundbeck) and biotechnology field (Intercell, now Valneva) and is specialized in neurology/psychiatry indications and vaccine development. Her expertise is available throughout the clinical development pipeline: from the conduct of clinical trials to drug approval. Ms. Bürger has been appointed by the works council as a delegate to the supervisory board.
Claudia Juno studied biomedical analytics at the Vienna General Hospital and has been employed at AFFiRiS AG since 2008. She has gained longstanding laboratory experience in university and industry settings from the Max F. Perutz Laboratories, the University College London and Baxter BioScience among others. At AFFiRiS Ms. Juno has worked on several projects in Parkinson’s disease and CETP. Since 2012, she is part of the PCSK9 project team. Ms. Juno has been appointed by the works council as a delegate to the supervisory.